Japanese pharmaceutical manufacturer Takeda is considering selling its plant to Yaroslavl, where more than 117 million euros have been invested, Kommersant writes, citing two people familiar with the matter.
According to the interlocutors of the newspaper, a number of companies have already been interested in the cost of the enterprise, but so far no specific negotiations are underway. One of the regional officials also heard about the possible sale of this asset by a Japanese company. At the same time, Takeda’s Russian office called the information a “market rumor”.
Takeda Pharmaceutical Company is Asia’s largest pharmaceutical company and one of the 15 largest in the world. Among the company’s drugs in the CIS market are Actovegin, Cardiomagnyl, Calcium-D3 Nycomed, Ceraxon, Xymelin, Xefocam and others.
According to SPARK, in 2021, the revenue of Takeda Pharmaceutical, the Russian legal entity of the company, amounted to 21.9 billion rubles, which is 22% more than in the previous year.
One of the sources specified that Takeda, like other foreign pharmaceutical manufacturers after the outbreak of the conflict in Ukraine, faced demands from some of its shareholders to reduce its presence in the Russian market. At the same time, according to him, the sale of the Yaroslavl plant does not mean that the company is completely curtailing its Russian business. Takeda said a year ago that it “does not see any risks to its operations in Russia.”
After the start of the military operation in Ukraine, some foreign pharmaceutical companies stopped working in Russia or stopped supplying their products to the country. In particular, Bayer, Pfizer, MSD and Novartis announced the suspension of investment activities and clinical trials in Russia. Eli Lilly and Bristol-Myers Squibb transferred the Russian business.
Source: Rosbalt
Mario Twitchell is an accomplished author and journalist, known for his insightful and thought-provoking writing on a wide range of topics including general and opinion. He currently works as a writer at 247 news agency, where he has established himself as a respected voice in the industry.
